Rare & Genetic · Clinical trials
Pompe Disease Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About pompe disease — and why its trials are hard
Pompe disease is a rare autosomal-recessive lysosomal storage disorder caused by deficiency of acid alpha-glucosidase (GAA), leading to progressive glycogen accumulation in cardiac, skeletal, and respiratory muscle. It spans a continuum from rapidly fatal infantile-onset disease (cardiomyopathy, hypotonia, early death without treatment) to slowly progressive late-onset disease dominated by limb-girdle weakness and respiratory failure. Enzyme replacement therapy (ERT) transformed the natural history: alglucosidase alfa (Myozyme/Lumizyme) became the first approved treatment in 2006 and remains the backbone. Two next-generation therapies followed, both engineered to improve mannose-6-phosphate-mediated muscle uptake: avalglucosidase alfa (Nexviazyme, 2021) and the two-component cipaglucosidase alfa plus the enzyme stabilizer miglustat (Pombiliti + Opfolda, 2023). Key efficacy measures are respiratory (forced vital capacity) and ambulatory (6-minute walk distance) function. Despite ERT, unmet need persists in reversing established damage, CNS involvement, and antibody responses, driving ongoing gene therapy and next-generation ERT development.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| alglucosidase alfa (Myozyme / Lumizyme) | 2006 | Infantile-onset and late-onset Pompe disease (ERT backbone) | Pivotal infantile-onset ERT study (Kishnani et al.) | Survival and ventilator-free survival vs untreated historical controls | Markedly reduced risk of death and invasive ventilation vs historical natural-history cohort in infantile-onset disease |
| avalglucosidase alfa (Nexviazyme) | 2021 | Late-onset Pompe disease (age >=1 yr) | COMET (Phase 3, vs alglucosidase alfa) | Change in upright FVC (% predicted) at week 49 (non-inferiority) | FVC improvement ~2.9% (avalglucosidase) vs ~0.5% (alglucosidase); between-group difference ~2.4%; met non-inferiority (superiority not formally met) |
| cipaglucosidase alfa + miglustat (Pombiliti + Opfolda) | 2023 | Late-onset Pompe disease in adults inadequately controlled on ERT (>=40 kg, not improving) | PROPEL (Phase 3, vs alglucosidase alfa + placebo) | Change in 6-minute walk distance (6MWD) at week 52 | Numerically favored cipaglucosidase+miglustat (~+14 m difference) but did not reach statistical significance for superiority (p~0.07); FVC secondary endpoint favored the combination |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in pompe disease development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| cipaglucosidase alfa + miglustat (superiority claim) — PROPEL | Primary endpoint (6MWD superiority vs alglucosidase alfa) not statistically met | Active comparator design and heterogeneous late-onset population narrowed the treatment difference; approval rested on totality of data rather than a positive primary endpoint |
Choosing the right endpoint
Primary endpoints that matter in pompe disease trials
- Forced vital capacity (FVC % predicted) — Primary respiratory measure in late-onset trials; captures diaphragmatic/respiratory muscle involvement, a key driver of morbidity and mortality
- 6-minute walk distance (6MWD) — Standard ambulatory/functional endpoint for limb-girdle weakness in late-onset disease
- Ventilator-free survival — Critical outcome in infantile-onset disease reflecting cardiorespiratory failure
- Motor function scales (e.g., GMFM, QMFT) — Assess gross/skeletal motor performance, especially in pediatric infantile-onset cohorts
How iNGENū runs pompe disease trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Pompe Disease clinical trials — FAQs
Is there a cure for Pompe disease?
How do avalglucosidase alfa and cipaglucosidase alfa differ from the original ERT?
What outcomes are measured in Pompe trials?
Ready to discuss your pompe disease trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal